Discovery of AZD0364, a potent and selective oral inhibitor of ERK1/2 that is efficacious in both monotherapy and combination therapy in models of NSCLC

被引：0

作者：

Simpson, Iain ^{[1
]}

Anderton, Mark J. ^{[1
]}

Andrews, David M. ^{[1
]}

Breed, Jason ^{[1
]}

Davies, Emma ^{[1
]}

Debreczeni, Judit E. ^{[1
]}

Flemington, Vikki ^{[1
]}

Gibbons, Francis D. ^{[2
]}

Graham, Mark A. ^{[1
]}

Hopcroft, Philip ^{[1
]}

Howard, Tina ^{[1
]}

Hudson, Julian ^{[1
]}

Jones, Clifford D. ^{[1
]}

Jones, Christopher ^{[1
]}

Lindsay, Nicola ^{[1
]}

Pease, J. Elizabeth ^{[1
]}

Rawlins, Philip ^{[1
]}

Roberts, Karen ^{[1
]}

Swallow, Steve ^{[1
]}

St-Gallay, Steve ^{[1
]}

Tonge, Michael E. ^{[1
]}

Ward, Richard A. ^{[1
]}

机构：

[1] AstraZeneca, Cambridge, England

[2] AstraZeneca, Boston, MA USA

来源：

CANCER RESEARCH | 2018年 / 78卷 / 13期

关键词：

D O I：

10.1158/1538-7445.AM2018-1647

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1647

引用

页数：3

共 50 条

[21] AZD6244 (ARRY-142886), a potent and selective MEK1/2 inhibitor blocks the ERK1/2 signaling pathway, inhibits osteoclast differentiation and activation in multiple myeloma: Clinical implications.
Breitkreutz, Iris
Vallet, Sonia
Raab, Marc S.
Li, Xianfeng
Raje, Noopur
Hideshima, Teru
Chauhan, Dharminder
Munshi, Nikhil
Anderson, Kenneth C.
Tai, Yu-Tzu
BLOOD, 2006, 108 (11) : 989A - 989A
[22] Evaluating the combination of datopotamab deruxtecan (Dato-DXd) with AZD5305, a highly potent, PARP1-selective inhibitor, -in preclinical models
Patel, Gopi
Owusu, Joe'l
Rane, Chetan
Rosen, Alan
Griffin, Matthew
Sung, Matthew
CANCER RESEARCH, 2024, 84 (06)
[23] The combination of ulixertinib(ERK1/2 Inhibitor) and KRASG12C inhibition demonstrates significant efficacy in preclinical models
Knoerzer, Deborah
Reddy, Anupama
Box, Jessica A.
Groover, Anna
Kreider, Brent
Teresk, Martin
Emery, Caroline M.
CANCER RESEARCH, 2023, 83 (07)
[24] ERAS-007 is a selective ERK1/2 inhibitor with preclinical activity across RAS/MAPK pathwaydriven CRC models
Lew, Erin D.
Oh, Joanne
Congdon, Taylor
Zhang, Jingchuan
Shoemaker, Robert F.
CANCER RESEARCH, 2022, 82 (12)
[25] BGB-15025, a potent and selective HPK1 inhibitor, is efficacious as a single agent or in combination with PD-1 antibody in multiple tumor models.
Liu, Ye
Li, Jing
Li, Zhuo
Wang, Qin
Zhou, Xing
Liu, Xiaoxin
Zhang, Bo
Wang, Xitao
Xu, Sanjia
Sun, Hanzi
Song, Xiaomin
Yuan, Xi
Wang, Zhiwei
Liu, Xuesong
CANCER RESEARCH, 2022, 82 (12)
[26] Significant efficacy demonstrated with the combination of ulixertinib (ERK1/2 inhibitor) and CDK4/6 inhibitors in MAPK altered models
Emery, Caroline M.
Corgiat, Brian
Davis, Justin
Sorrell, David
Johnson, Mitch
Kreider, Brent
Knoerzer, Deborah
CANCER RESEARCH, 2022, 82 (12)
[27] A novel ERK1/2 inhibitor has potent activity in KRAS-mutant non-small cell lung cancer models
Courtin, Aurelie
Bevan, Luke
Heightman, Tom
Kidane, Birikiti
Kucia-Tran, Justyna
Lyons, John
Muench, Sandra
Shah, Alpesh
Stanczuk, Lukas
Thompson, Neil
Wallis, Nicola
Wilsher, Nicola
Munck, Joanne
CANCER RESEARCH, 2018, 78 (13)
[28] Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models
Yiqing Qu
Xiuxiu Wu
Yunhong Yin
Yan Yang
Dedong Ma
Hao Li
Journal of Experimental & Clinical Cancer Research, 33
[29] Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models
Qu, Yiqing
Wu, Xiuxiu
Yin, Yunhong
Yang, Yan
Ma, Dedong
Li, Hao
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2014, 33
[30] A first in human phase I study of AZD81 86, a potent and selective inhibitor of PI3K in patients with advanced solid tumours as monotherapy and in combination with the dual mTORC1/2 inhibitor vistusertib (AZD2014) or abiraterone acetate.
Hansen, Aaron Richard
Shapiro, Geoffrey
Do, Khanh T.
Kumar, Rajiv
Martin-Liberal, Juan
Higano, Celestia S.
Wisinski, Kari Braun
Dean, Emma Jane
Heath, Elisabeth I.
Dana, E. Rathkopf
Linch, Mark David
Barry, Simon T.
Brugger, Wolfram
De Bruin, Elza
Colebrook, Steve
Klinowska, Teresa
Mitchell, Patrick D.
Moorthy, Ganesh
De Bono, Johann S.
Siu, Lillian L.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

← 1 2 3 4 5 →